Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Sari D. Hopson, PhD, MSPH
Advertisement
Articles by Sari D. Hopson, PhD, MSPH
Advertisement
Latest Updated Articles
- COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis
Published: May 6th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Energy Insecurity Linked to Higher Depression, Anxiety in US Adults
2
FDA Expands Sotatercept Indication for PAH
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
5
